VINC.US
VINC.US

Last Day

Biotechnology

Latest Valuation

  • Trailing PE:
  • Forward PE:
  • Price Sales TTM:
  • Price Book MRQ:
  • Enterprise Value:
  • Enterprise Value Revenue:
  • Enterprise Value Ebitda:
  • Beta:

Key Highlights

  • Shares Outstanding:
  • Market Capitalization:
  • Market Capitalization Mln:
  • EBITDA:
  • PE Ratio:
  • PEG Ratio:
  • Wall Street Target Price:
  • Book Value:
  • Dividend Share:
  • Dividend Yield:
  • Earnings Share:
  • EPS Estimate Current Year:
  • EPS Estimate Next Year:
  • EPS Estimate Next Quarter:
  • EPS Estimate Current Quarter:
  • Most Recent Quarter:
  • Profit Margin:
  • Operating Margin TTM:
  • Return On Assets TTM:
  • Return On Equity TTM:
  • Revenue TTM:
  • Revenue Per Share TTM:
  • Quarterly Revenue Growth YOY:
  • Gross Profit TTM:
  • Diluted Eps TTM:
  • Quarterly Earnings Growth YOY:

Basic Information

  • Type:
  • Name:
  • Exchange:
  • Currency Code:
  • Currency Name:
  • Currency Symbol:
  • Country Name:
  • Fiscal Year End:
  • IPO Date:
  • International Domestic:
  • Sector:
  • Industry:
  • Address:
  • Country:
  • Listings:
  • Web URL:
  • Full Time Employees:
  • Updated At:
  • Gic Sector:
  • Gic Group:
  • Gic Industry:
  • Gic SubIndustry:

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California. Address: 260 Sheridan Avenue, Palo Alto, CA, United States, 94306

2024-6-30